Novartis AG (SWX:NOVN)
95.42
+0.21 (0.22%)
Jun 20, 2025, 12:46 PM CET
Novartis AG Revenue
Novartis AG had revenue of $13.62B USD in the quarter ending March 31, 2025, with 12.38% growth. This brings the company's revenue in the last twelve months to $53.22B, up 11.50% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
$53.22B
Revenue Growth
+11.50%
P/S Ratio
3.97
Revenue / Employee
$701.37K
Employees
75,883
Market Cap
186.54B CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 62.40B |
Lonza Group AG | 6.57B |
Alcon | 8.77B |
Galderma Group AG | 4.02B |
Sandoz Group AG | 9.41B |
Straumann Holding AG | 2.50B |
Sonova Holding AG | 3.87B |
Ypsomed Holding AG | 748.87M |
Novartis AG News
- 2 days ago - Divi’s Laboratories shares in focus after Novartis and MSN settle on Entresto 659 patent - Business Upturn
- 7 days ago - Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder - Benzinga
- 8 days ago - Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH - GlobeNewsWire
- 17 days ago - Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug - Benzinga
- 18 days ago - Novartis' Pluvicto shown to slow prostate cancer in earlier setting - Reuters
- 18 days ago - Novartis's Cancer Treatment Pluvicto Shows Positive Results in Trial - WSJ
- 18 days ago - Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer - GlobeNewsWire
- 21 days ago - Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019 - Benzinga